Evidence map›Paper›PMID 23045281›Full record

ArticleOncogene2013

Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.

P K Manchanda, G N Jones, A A Lee, D R Pringle, M Zhang, L Yu, K M D La Perle, L S Kirschner

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Co-Existing Ectopic Cortisol-Producing Adenoma and Retroperitoneal Schwannoma, a Rare Case Report.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Schwannomas and their pathogenesis.Brain pathology (Zurich, Switzerland) · 2014
    Review
  13. Article
  14. The protein kinase A regulatory subunit R1A (Prkar1a) plays critical roles in peripheral nerve development.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

P K ManchandaDepartment of Molecular, Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
G N Jones
A A Lee
D R Pringle
M Zhang
L Yu
K M D La Perle
L S Kirschner
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Selective Modulation of Thyroidal RadioiodineP01CA124570 · NCI · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2008 to 2017
$23.4M
Carney Complex: A Model for PKA-Mediated TumorigenesisR01CA112268 · NCI · OHIO STATE UNIVERSITY · PI KIRSCHNER, LAWRENCE S · 2004 to 2008
$1.3M
NCI NIH HHS P01 CA124570NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA112268
6 · The paper itself

Abstract

Schwannomas are peripheral nerve sheath tumors that often occur in the setting of an inherited tumor predisposition syndrome, including neurofibromatosis types 1 (NF1) and 2 (NF2), familial schwannomatosis and Carney complex. Loss of the NF2 tumor suppressor (encoding NF2, or Merlin) is associated with upregulation of the Rac1 small GTPase, which is thought to have a key role in mediating tumor formation. In prior studies, we generated a mouse model of schwannomas by performing tissue-specific knockout (KO) of the Carney complex gene Prkar1a, which encodes the type 1A regulatory subunit of protein kinase A. These tumors exhibited down-regulation of Nf2 protein and an increase in activated Rac1. To assess the requirement for Rac1 in schwannoma formation, we generated a double KO (DKO) of Prkar1a and Rac1 in Schwann cells and monitored tumor formation. Loss of Rac1 reduced tumor formation by reducing proliferation and enhancing apoptosis. Surprisingly, the reduction of tumor formation was accompanied by re-expression of the Nf2 protein. Furthermore, activated Rac1 was able to downregulate Nf2 in vitro in a Pak-dependent manner. These in vivo data indicate that activation of Rac1 is responsible for suppression of Nf2 protein production; deficiency of Nf2 in Schwann cells leads to loss of cellular growth control and tumor formation. Further, PKA activation through mutation in Prkar1a is sufficient to initiate Rac1 signaling, with subsequent reduction of Nf2 and schwannomagenesis. Although in vitro evidence has shown that loss of Nf2 activates Rac1, our data indicate that signaling between Nf2 and Rac1 occurs in a bidirectional fashion, and these interactions are modulated by PKA.

Indexed as

Genes, Neurofibromatosis 2AnimalsCyclic AMP-Dependent Protein Kinase RIalpha SubunitDown-RegulationMiceMice, KnockoutNeurilemmomaNeuropeptidesrac1 GTP-Binding Proteinrac GTP-Binding ProteinsSchwann CellsCyclic AMP-Dependent Protein Kinase RIalpha SubunitNeuropeptidesPrkar1a protein, mouserac1 GTP-Binding ProteinRac1 protein, mouserac GTP-Binding Proteins

Identifiers

PMID23045281
PMCPMC3542412
OpenAlexW2069779612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.